Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 | Q9NR97 | 11/20 | 0.41 |
| ▸ | TLR7 | Q9NYK1 | 8/20 | 0.41 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | HEXA | P06865 | 1/20 | 0.36 |
| ▸ | HEXB | P07686 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15434720 | 0.86 | TLR8 (0.39) | TLR8TLR7MAPK1KDM4EHEXA | |
| SCHEMBL9286489 | 0.81 | NOS3 (0.39) | TLR8TLR7MAPK1KDM4EALDH1A1 | |
| SCHEMBL9286486 | 0.79 | TLR8 (0.52) | TLR8TLR7 | |
| SCHEMBL15434700 | 0.74 | TLR8 (0.45) | TLR8TLR7HSP90AA1MAPK1HEXA | |
| SCHEMBL15429559 | 0.74 | MAPK1 (0.34) | TLR8TLR7MAPK1KDM4EALDH1A1 | |
| SCHEMBL16229363 | 0.73 | TLR8 (0.65) | TLR8TLR7 | |
| SCHEMBL17229299 | 0.70 | NOS2 (0.44) | KDM4EALDH1A1 | |
| SCHEMBL27544017 | 0.70 | HEXA (0.49) | MAPK1KDM4EHEXAHEXBPOLB | |
| SCHEMBL2072604 | 0.68 | HEXA (0.46) | HSP90AA1MAPK1KDM4EHEXAHEXB | |
| SCHEMBL15429545 | 0.68 | TLR8 (0.42) | TLR8TLR7MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012071519-A1 | BENZOXAZEPINES AS INHIBITORS OF P13K/MTOR AND METHODS OF THEIR USE AND MANUFACTURE | EXELIXIS, INC. (US) | 2012-05-31 | — | — | WO | disclosed |